Drugs / Emtricitabine/Tenofovir Disoproxil Fumarate
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06101329 | Nov 2023 → Jul 2026 overdue | — | Gilead Sciences | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emtricitabine/Tenofovir Disoproxil Fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06101329 ↗ |
| Route | Oral | “200/300mg fixed dose combination (FDC) tablets administered orally” NCT06101329 ↗ |